Prospective Registry of Iclusig (Ponatinib) Used in Clinical Practice for the Treatment of Patients With Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
Phase of Trial: Phase IV
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Incyte Biosciences International
- 06 Nov 2019 Results evaluating real life outcomes (n=50) released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 10 Apr 2019 Planned End Date changed from 30 Nov 2019 to 31 Jul 2022.
- 10 Apr 2019 Planned primary completion date changed from 9 Jul 2019 to 31 Mar 2022.